Neuschwander-Tetri BA - Search Results

1

TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial.

Loomba R, Mohseni R, Lucas KJ, Gutierrez JA, Perry RG, Trotter JF, Rahimi RS, Harrison SA, Ajmera V, Wayne JD, O'Farrell M, McCulloch W, Grimmer K, Rinella M, Wai-Sun Wong V, Ratziu V, Gores GJ, Neuschwander-Tetri BA, Kemble G. Loomba R, et al. Gastroenterology. 2021 Nov;161(5):1475-1486. doi: 10.1053/j.gastro.2021.07.025. Epub 2021 Jul 23. Gastroenterology. 2021. PMID: 34310978 Free article. Clinical Trial.

2

Evolving pathophysiologic concepts in nonalcoholic steatohepatitis.

Neuschwander-Tetri BA. Neuschwander-Tetri BA. Curr Gastroenterol Rep. 2002 Feb;4(1):31-6. doi: 10.1007/s11894-002-0035-x. Curr Gastroenterol Rep. 2002. PMID: 11825539 Review.

3

Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.

Neuschwander-Tetri BA, Caldwell SH. Neuschwander-Tetri BA, et al. Hepatology. 2003 May;37(5):1202-19. doi: 10.1053/jhep.2003.50193. Hepatology. 2003. PMID: 12717402 Review.

4

Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone.

Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Neuschwander-Tetri BA, et al. Hepatology. 2003 Oct;38(4):1008-17. doi: 10.1053/jhep.2003.50420. Hepatology. 2003. PMID: 14512888 Clinical Trial.

5

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Harrison SA, Neuschwander-Tetri BA. Harrison SA, et al. Clin Liver Dis. 2004 Nov;8(4):861-79, ix. doi: 10.1016/j.cld.2004.06.008. Clin Liver Dis. 2004. PMID: 15464659 Review.

6

Effect of significant histologic steatosis or steatohepatitis on response to antiviral therapy in patients with chronic hepatitis C.

Harrison SA, Brunt EM, Qazi RA, Oliver DA, Neuschwander-Tetri BA, Di Bisceglie AM, Bacon BR. Harrison SA, et al. Clin Gastroenterol Hepatol. 2005 Jun;3(6):604-9. doi: 10.1016/s1542-3565(05)00246-6. Clin Gastroenterol Hepatol. 2005. PMID: 15952103

7

Nonalcoholic steatohepatitis and the metabolic syndrome.

Neuschwander-Tetri BA. Neuschwander-Tetri BA. Am J Med Sci. 2005 Dec;330(6):326-35. doi: 10.1097/00000441-200512000-00011. Am J Med Sci. 2005. PMID: 16355018 Review.

8

Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction.

Richardson MM, Jonsson JR, Powell EE, Brunt EM, Neuschwander-Tetri BA, Bhathal PS, Dixon JB, Weltman MD, Tilg H, Moschen AR, Purdie DM, Demetris AJ, Clouston AD. Richardson MM, et al. Gastroenterology. 2007 Jul;133(1):80-90. doi: 10.1053/j.gastro.2007.05.012. Epub 2007 May 16. Gastroenterology. 2007. PMID: 17631134

9

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial.

Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Harrison SA, et al. Hepatology. 2009 Jan;49(1):80-6. doi: 10.1002/hep.22575. Hepatology. 2009. PMID: 19053049 Clinical Trial.

10

Treatment of nonalcoholic fatty liver disease in children: TONIC trial design.

Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM, Unalp A, Tonascia J; Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Lavine JE, et al. Contemp Clin Trials. 2010 Jan;31(1):62-70. doi: 10.1016/j.cct.2009.09.001. Epub 2009 Sep 15. Contemp Clin Trials. 2010. PMID: 19761871 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

198 results

Search Page